2.49

2.35% -0.06

After Hours: 2.65 0.16 +6.43%

Connect Biopharma Holdings Ltd (CNTB)

Overview News Price History Option Chain Discussions Forecast

Connect Biopharma Holdings Ltd stock is traded at $2.49, with a volume of 577.15K. It is down -2.35% in the last 24 hours and up +4.62% over the past month. Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Previous Close:

$2.55

Open:

$2.57

24h Volume:

577.15K

Relative Volume:

1.41

Market Cap:

$156.81M

Revenue:

$233.00K

Net Income/Loss:

$-64.61M

P/E Ratio:

-2.1585

EPS:

-1.1536

Net Cash Flow:

$-58.32M

1W Performance:

+15.81%

1M Performance:

+4.62%

6M Performance:

-12.32%

1Y Performance:

+21.46%

1-Day Range:

$2.47

$2.61

1-Week Range:

$2.13

$2.64

52-Week Range:

$1.23

$3.82

Connect Biopharma Holdings Ltd Stock (CNTB) Company Profile

Name

Connect Biopharma Holdings Ltd

Sector

Healthcare (1082)

Industry

Biotechnology (606)

Phone

858-727-1040

Address

3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

CNTB's Discussions on Twitter

Compare CNTB vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CNTB Connect Biopharma Holdings Ltd	2.49	160.58M	233.00K	-64.61M	-58.32M	-1.1536
VRTX Vertex Pharmaceuticals Inc	515.55	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.93	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	987.84	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.00	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.51	39.31B	5.76B	514.49M	1.10B	4.4813

Connect Biopharma Holdings Ltd Stock (CNTB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-01-25	Initiated	Lake Street	Buy
Oct-31-25	Initiated	BTIG Research	Buy
Jun-12-25	Initiated	H.C. Wainwright	Buy
Mar-04-24	Initiated	H.C. Wainwright	Buy
Apr-13-21	Initiated	Jefferies	Buy
Apr-13-21	Initiated	Piper Sandler	Overweight
Apr-13-21	Initiated	SVB Leerink	Outperform

View All

Connect Biopharma Holdings Ltd Stock (CNTB) Latest News

09:32 AM

Connect Biopharma Holdings Ltd reports results for the quarter ended June 30Earnings Summary - TradingView

09:32 AM

01:17 AM

HC Wainwright Issues Pessimistic Forecast for CNTB Earnings - MarketBeat

01:17 AM

Aug 15, 2026

Connect Biopharma (NASDAQ:CNTB) Upgraded by Wall Street Zen to Hold Rating - MarketBeat

Aug 15, 2026

Aug 14, 2026

Ikarian Capital (CNTB) discloses 6.9% Connect Biopharma holding on Schedule 13G/A - Stock Titan

Aug 14, 2026

Connect Biopharma (CNTB) investor Wei Zheng discloses 4% beneficial stake - Stock Titan

Aug 14, 2026

Connect Biopharma Holdings Ltd expected to post a loss of 21 cents a shareEarnings Preview - TradingView

Aug 14, 2026

Aug 13, 2026

H.C. Wainwright Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Aug 13, 2026

Connect Biopharma Holdings earnings beat by ¥0.34, revenue topped estimates - Investing.com Canada

Aug 13, 2026

Aug 12, 2026

Connect Biopharma Q2 Results: Net Loss Widens To $17.3 Million - scanx.trade

Aug 12, 2026

Connect Biopharma (NASDAQ:CNTB) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat

Aug 12, 2026

Connect Biopharma (CNTB) ramps rademikibart spend as losses deepen in 2026 - Stock Titan

Aug 12, 2026

Connect Biopharma Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 12, 2026

Connect Biopharma (CNTB) widens Q2 2026 loss as R&D rises, cash at $31.5M - Stock Titan

Aug 12, 2026

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire

Aug 12, 2026

Aug 10, 2026